Cytek Biosciences (CTKB) Financials

$3.96 +0.19 (+5.04%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 0.00 (-0.13%)

As of 04:39 PM Eastern

Annual Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	2.58	-12	-6.02
Consolidated Net Income / (Loss)	2.48	-12	-6.02
Net Income / (Loss) Continuing Operations	2.48	-12	-6.02
Total Pre-Tax Income	1.26	-16	-5.70
Total Operating Income	-1.80	-28	-21
Total Gross Profit	101	109	111
Total Revenue	164	193	200
Operating Revenue	164	193	200
Total Cost of Revenue	63	84	89
Operating Cost of Revenue	63	84	89
Total Operating Expenses	103	137	132
Selling, General & Admin Expense	35	44	43
Marketing Expense	33	49	49
Research & Development Expense	35	44	39
Total Other Income / (Expense), net	3.06	12	15
Interest Expense	2.57	2.07	-5.24
Interest & Investment Income	4.62	6.41	5.12
Other Income / (Expense), net	1.02	7.79	4.46
Income Tax Expense	-1.22	-3.56	0.32
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.09	0.00	0.00
Weighted Average Basic Shares Outstanding	134.51M	135.28M	130.61M
Weighted Average Diluted Shares Outstanding	138.56M	135.28M	130.61M
Weighted Average Basic & Diluted Shares Outstanding	135.43M	130.82M	128.10M

This table shows Cytek Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.67	3.53	-6.81	-4.39	-6.46	5.50	-6.17	-10	0.94	9.64
Consolidated Net Income / (Loss)	1.63	3.72	-6.81	-4.39	-6.46	5.50	-6.17	-10	0.94	9.64
Net Income / (Loss) Continuing Operations	1.63	3.72	-6.81	-4.39	-6.46	5.50	-6.17	-10	0.94	9.64
Total Pre-Tax Income	1.85	4.11	-9.04	-6.60	-4.19	4.11	-8.99	-7.19	0.16	10
Total Operating Income	1.36	0.08	-12	-9.13	-6.42	-0.14	-11	-8.53	-4.25	2.99
Total Gross Profit	27	29	21	28	27	33	23	25	29	34
Total Revenue	40	48	37	50	48	58	45	47	52	57
Operating Revenue	40	48	37	50	48	58	45	47	52	57
Total Cost of Revenue	14	19	16	22	21	25	22	21	22	24
Operating Cost of Revenue	14	19	16	22	21	25	22	21	22	24
Total Operating Expenses	26	29	33	37	34	33	34	34	33	31
Selling, General & Admin Expense	8.04	11	12	11	10	11	11	12	11	9.07
Marketing Expense	8.81	9.03	11	14	12	12	13	12	12	12
Research & Development Expense	8.65	9.75	9.97	12	11	11	9.80	10	9.88	9.72
Total Other Income / (Expense), net	0.49	4.03	3.12	2.53	2.24	4.25	1.74	1.34	4.41	7.34
Interest Expense	0.65	0.69	0.67	0.41	0.60	0.39	0.44	0.13	0.12	-5.93
Interest & Investment Income	1.58	2.63	2.14	1.20	1.62	1.45	1.36	1.42	1.43	0.91
Other Income / (Expense), net	-0.45	2.09	1.65	1.74	1.21	3.19	0.82	0.06	3.09	0.49
Income Tax Expense	0.22	0.40	-2.23	-2.21	2.27	-1.39	-2.82	3.25	-0.78	0.68
Weighted Average Basic Shares Outstanding	134.71M	134.51M	135.49M	135.92M	136.17M	135.28M	130.92M	131.44M	131.00M	130.61M
Weighted Average Diluted Shares Outstanding	138.71M	138.56M	135.49M	135.92M	136.17M	135.28M	130.92M	131.44M	132.79M	130.61M
Weighted Average Basic & Diluted Shares Outstanding	134.85M	135.43M	135.67M	136.36M	135.55M	130.82M	131.27M	131.51M	128.81M	128.10M

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-65	-132	-69
Net Cash From Operating Activities	-12	5.28	25
Net Cash From Continuing Operating Activities	-12	7.48	25
Net Income / (Loss) Continuing Operations	2.48	-12	-6.02
Consolidated Net Income / (Loss)	2.48	-12	-6.02
Depreciation Expense	2.49	6.05	7.21
Amortization Expense	3.09	-	-1.93
Non-Cash Adjustments To Reconcile Net Income	17	21	18
Changes in Operating Assets and Liabilities, net	-38	-7.10	8.03
Net Cash From Investing Activities	-56	-94	-83
Net Cash From Continuing Investing Activities	-56	-94	-83
Purchase of Property, Plant & Equipment	-9.75	-4.69	-3.53
Acquisitions	-0.12	-45	-0.68
Purchase of Investments	-46	-176	-274
Sale of Property, Plant & Equipment	0.00	0.00	0.29
Sale and/or Maturity of Investments	0.00	132	195
Net Cash From Financing Activities	5.51	-42	-16
Net Cash From Continuing Financing Activities	5.51	-44	-16
Repayment of Debt	-0.05	-0.57	-0.56
Repurchase of Common Equity	0.00	-44	-22
Issuance of Debt	2.98	0.00	4.18
Other Financing Activities, net	2.58	1.05	2.17
Effect of Exchange Rate Changes	-2.49	-	4.53
Cash Income Taxes Paid	10	5.31	3.83

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-8.37	-42	-167	-0.85	33	3.38	1.51	8.78	-16	-64
Net Cash From Operating Activities	-7.50	6.19	2.86	-2.85	-4.24	9.51	3.96	6.20	13	2.00
Net Cash From Continuing Operating Activities	-7.50	6.19	3.45	-3.44	-4.24	12	3.96	6.20	13	2.00
Net Income / (Loss) Continuing Operations	1.63	3.72	-6.81	-4.39	-6.46	5.50	-6.17	-10	0.94	9.64
Consolidated Net Income / (Loss)	1.63	3.72	-6.81	-4.39	-6.46	5.50	-6.17	-10	0.94	9.64
Depreciation Expense	0.07	0.76	1.00	1.65	1.77	1.63	1.70	1.81	1.85	1.85
Amortization Expense	0.70	1.03	-	-	-0.77	-	-0.44	-0.51	-0.29	-0.69
Non-Cash Adjustments To Reconcile Net Income	5.90	3.14	4.50	7.56	6.49	2.13	7.02	7.23	7.46	-3.62
Changes in Operating Assets and Liabilities, net	-16	-2.46	4.75	-6.15	-5.27	-0.43	1.85	8.11	3.26	-5.18
Net Cash From Investing Activities	-1.15	-51	-169	2.79	43	29	-5.75	2.02	-16	-63
Net Cash From Continuing Investing Activities	-1.15	-51	-169	2.69	43	29	-5.75	2.02	-16	-63
Purchase of Property, Plant & Equipment	-1.11	-6.53	-0.64	-1.17	-1.33	-1.54	-0.57	-1.05	-1.01	-0.89
Acquisitions	-0.04	-0.08	-45	-0.06	-0.06	-0.06	-0.06	-0.15	0.01	-0.48
Purchase of Investments	-	-44	-123	-6.08	-23	-23	-77	-37	-53	-107
Sale of Property, Plant & Equipment	-	-	-	-	-	-	-	-	0.02	0.19
Sale and/or Maturity of Investments	-	-	0.00	10	68	54	72	40	38	45
Net Cash From Financing Activities	0.16	3.85	0.00	0.22	-8.27	-34	1.61	-1.71	-12	-3.64
Net Cash From Continuing Financing Activities	0.16	3.85	0.00	0.22	-8.27	-36	1.61	-1.71	-12	-3.64
Repayment of Debt	-	-0.05	-0.15	-0.14	-0.14	-0.14	-0.14	-0.14	-0.14	-0.14
Repurchase of Common Equity	-	-	-	-	-8.43	-35	-	-	-12	-6.99
Issuance of Debt	-	-	0.00	-	-	-	1.39	-0.00	0.01	2.79
Other Financing Activities, net	0.16	0.92	0.15	0.37	0.29	0.24	0.36	0.09	0.00	1.71
Effect of Exchange Rate Changes	0.13	-1.00	-	-	-	-	1.70	2.26	-0.94	1.52
Cash Income Taxes Paid	2.27	0.46	0.09	0.59	0.13	4.50	0.00	1.06	0.86	1.91

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	519	494	500
Total Current Assets	454	392	396
Cash & Equivalents	297	167	99
Restricted Cash	2.90	0.33	0.03
Short-Term Investments	45	95	179
Accounts Receivable	49	56	61
Inventories, net	48	61	44
Prepaid Expenses	13	13	14
Plant, Property, & Equipment, net	14	18	18
Total Noncurrent Assets	52	84	85
Goodwill	10	16	17
Intangible Assets	4.33	23	20
Noncurrent Deferred & Refundable Income Taxes	20	30	33
Other Noncurrent Operating Assets	17	14	15
Total Liabilities & Shareholders' Equity	519	494	500
Total Liabilities	94	101	104
Total Current Liabilities	49	56	68
Accounts Payable	4.81	3.03	5.53
Accrued Expenses	21	20	21
Current Deferred Revenue	13	23	25
Other Current Liabilities	10	10	15
Total Noncurrent Liabilities	45	45	36
Asset Retirement Reserve & Litigation Obligation	16	16	9.04
Noncurrent Deferred Revenue	13	15	16
Other Noncurrent Operating Liabilities	16	14	11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	426	393	396
Total Preferred & Common Equity	426	393	396
Total Common Equity	426	393	396
Common Stock	443	424	431
Retained Earnings	-17	-29	-35
Accumulated Other Comprehensive Income / (Loss)	-0.70	-1.28	0.02

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	499	525	525	519	492	484	491
Total Current Assets	444	426	425	422	389	384	390
Cash & Equivalents	342	129	132	164	169	178	162
Restricted Cash	0.00	2.92	0.00	0.00	0.35	0.03	0.03
Short-Term Investments	-	170	167	124	101	99	116
Accounts Receivable	40	43	50	55	50	45	53
Inventories, net	49	70	66	67	55	50	47
Prepaid Expenses	13	11	11	12	13	12	13
Plant, Property, & Equipment, net	7.84	16	16	17	18	18	19
Total Noncurrent Assets	48	83	85	80	85	82	83
Goodwill	10	19	19	16	16	16	16
Intangible Assets	4.49	25	24	24	22	21	20
Noncurrent Deferred & Refundable Income Taxes	14	23	26	24	33	30	31
Other Noncurrent Operating Assets	19	16	15	15	14	14	15
Total Liabilities & Shareholders' Equity	499	525	525	519	492	484	491
Total Liabilities	83	101	101	104	99	95	106
Total Current Liabilities	41	57	54	59	56	52	63
Accounts Payable	5.64	5.28	3.08	4.71	3.73	3.19	5.39
Accrued Expenses	17	20	20	21	18	15	21
Current Deferred Revenue	12	18	21	23	23	24	25
Other Current Liabilities	7.12	13	10	10	11	9.73	11
Total Noncurrent Liabilities	41	45	47	45	44	42	43
Asset Retirement Reserve & Litigation Obligation	15	16	16	16	17	17	17
Noncurrent Deferred Revenue	10	13	16	15	15	14	15
Other Noncurrent Operating Liabilities	16	16	15	14	12	11	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	417	423	424	416	393	389	385
Total Preferred & Common Equity	417	423	424	416	393	389	385
Total Common Equity	417	423	424	416	393	389	385
Common Stock	438	448	454	452	430	435	430
Retained Earnings	-21	-24	-28	-35	-35	-46	-45
Accumulated Other Comprehensive Income / (Loss)	-0.53	-0.59	-1.76	-1.58	-1.55	-0.20	0.10

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	28.20%	17.67%	3.85%
EBITDA Growth	-45.94%	-391.97%	23.01%
EBIT Growth	-110.30%	-2,451.02%	19.90%
NOPAT Growth	-176.19%	-448.06%	26.30%
Net Income Growth	-17.94%	-589.05%	50.44%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-364.17%	143.18%	380.57%
Free Cash Flow Firm Growth	-85.09%	-54.26%	97.23%
Invested Capital Growth	99.91%	59.91%	-9.57%
Revenue Q/Q Growth	25.87%	5.41%	-0.38%
EBITDA Q/Q Growth	123.01%	20.47%	-13.62%
EBIT Q/Q Growth	96.90%	4.22%	2.54%
NOPAT Q/Q Growth	78.56%	-0.80%	13.20%
Net Income Q/Q Growth	203.54%	12.81%	40.74%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	5.74%	169.16%	-22.85%
Free Cash Flow Firm Q/Q Growth	0.00%	4.92%	-157.34%
Invested Capital Q/Q Growth	8.68%	2.21%	9.47%
Profitability Metrics	-	-	-
Gross Margin	61.56%	56.69%	55.43%
EBITDA Margin	2.92%	-7.25%	-5.38%
Operating Margin	-1.10%	-14.43%	-10.24%
EBIT Margin	-0.48%	-10.39%	-8.01%
Profit (Net Income) Margin	1.51%	-6.29%	-3.00%
Tax Burden Percent	197.14%	77.33%	105.61%
Interest Burden Percent	-160.31%	78.35%	35.49%
Effective Tax Rate	-97.14%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.82%	-18.40%	-11.58%
ROIC Less NNEP Spread (ROIC-NNEP)	-7.52%	-20.82%	-14.67%
Return on Net Nonoperating Assets (RNNOA)	6.42%	15.44%	10.05%
Return on Equity (ROE)	0.60%	-2.97%	-1.53%
Cash Return on Invested Capital (CROIC)	-72.45%	-64.50%	-1.52%
Operating Return on Assets (OROA)	-0.16%	-3.96%	-3.23%
Return on Assets (ROA)	0.51%	-2.40%	-1.21%
Return on Common Equity (ROCE)	0.60%	-2.97%	-1.53%
Return on Equity Simple (ROE_SIMPLE)	0.58%	-3.09%	-1.52%
Net Operating Profit after Tax (NOPAT)	-3.56	-19	-14
NOPAT Margin	-2.17%	-10.10%	-7.17%
Net Nonoperating Expense Percent (NNEP)	1.70%	2.42%	3.09%
Return On Investment Capital (ROIC_SIMPLE)	-0.84%	-4.96%	-3.63%
Cost of Revenue to Revenue	38.44%	43.31%	44.57%
SG&A Expenses to Revenue	21.15%	22.78%	21.51%
R&D to Revenue	21.25%	22.87%	19.66%
Operating Expenses to Revenue	62.66%	71.12%	65.67%
Earnings before Interest and Taxes (EBIT)	-0.79	-20	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.80	-14	-11
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.24	3.15	2.11
Price to Tangible Book Value (P/TBV)	3.35	3.49	2.33
Price to Revenue (P/Rev)	8.39	6.40	4.17
Price to Earnings (P/E)	534.49	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.19%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.67	7.47	4.74
Enterprise Value to Revenue (EV/Rev)	6.30	5.04	2.78
Enterprise Value to EBITDA (EV/EBITDA)	215.35	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	184.33	21.99
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.85	-0.74	-0.69
Leverage Ratio	1.18	1.24	1.26
Compound Leverage Factor	-1.90	0.97	0.45
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	10.00	8.30	5.82
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.26	6.97	5.86
Quick Ratio	7.95	5.66	5.00
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-44	-68	-1.89
Operating Cash Flow to CapEx	-125.47%	112.65%	784.03%
Free Cash Flow to Firm to Interest Expense	-17.21	-32.99	0.00
Operating Cash Flow to Interest Expense	-4.75	2.55	0.00
Operating Cash Flow Less CapEx to Interest Expense	-8.54	0.29	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.33	0.38	0.40
Accounts Receivable Turnover	4.17	3.68	3.44
Inventory Turnover	1.57	1.53	1.71
Fixed Asset Turnover	16.80	12.03	11.02
Accounts Payable Turnover	16.09	21.33	20.87
Days Sales Outstanding (DSO)	87.47	99.08	106.08
Days Inventory Outstanding (DIO)	232.46	238.05	214.00
Days Payable Outstanding (DPO)	22.69	17.11	17.49
Cash Conversion Cycle (CCC)	297.25	320.02	302.60
Capital & Investment Metrics	-	-	-
Invested Capital	81	130	118
Invested Capital Turnover	2.68	1.82	1.62
Increase / (Decrease) in Invested Capital	41	49	-12
Enterprise Value (EV)	1,033	973	558
Market Capitalization	1,377	1,236	836
Book Value per Share	$3.16	$2.90	$3.07
Tangible Book Value per Share	$3.05	$2.61	$2.79
Total Capital	426	393	396
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-344	-263	-278
Capital Expenditures (CapEx)	9.75	4.69	3.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	61	73	51
Debt-free Net Working Capital (DFNWC)	405	336	329
Net Working Capital (NWC)	405	336	329
Net Nonoperating Expense (NNE)	-6.04	-7.34	-8.35
Net Nonoperating Obligations (NNO)	-344	-263	-278
Total Depreciation and Amortization (D&A)	5.58	6.05	5.28
Debt-free, Cash-free Net Working Capital to Revenue	37.15%	37.87%	25.39%
Debt-free Net Working Capital to Revenue	246.88%	173.99%	164.02%
Net Working Capital to Revenue	246.88%	173.99%	164.02%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	134.51M	135.28M	130.61M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	138.56M	135.28M	130.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	135.43M	130.82M	128.10M
Normalized Net Operating Profit after Tax (NOPAT)	-1.26	-19	-14
Normalized NOPAT Margin	-0.77%	-10.10%	-7.17%
Pre Tax Income Margin	0.77%	-8.14%	-2.84%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-0.31	-9.68	0.00
NOPAT to Interest Expense	-1.38	-9.41	0.00
EBIT Less CapEx to Interest Expense	-4.09	-11.95	0.00
NOPAT Less CapEx to Interest Expense	-5.17	-11.68	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-363.44%	-358.99%

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.75%	230.57%	5.77%	23.74%	18.59%	20.48%	20.96%	-6.19%	7.29%	-1.30%
EBITDA Growth	-37.39%	118.28%	-654.08%	-1,502.93%	-349.94%	18.35%	9.00%	-24.97%	109.63%	-1.11%
EBIT Growth	-63.46%	109.73%	-284.84%	-545.15%	-669.62%	40.60%	5.70%	-14.63%	77.80%	13.67%
NOPAT Growth	-39.71%	-99.87%	-415.99%	-924.35%	-475.96%	-339.81%	11.74%	6.57%	-466.55%	1,632.15%
Net Income Growth	14.51%	419.14%	-215.43%	-525.07%	-497.05%	48.01%	9.37%	-137.78%	114.58%	75.21%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-746.34%	13.67%	293.11%	69.81%	43.51%	53.59%	38.45%	317.68%	411.89%	-79.01%
Free Cash Flow Firm Growth	-93.80%	0.00%	-82.73%	-83.72%	-20.36%	-20.54%	90.44%	110.63%	90.15%	131.15%
Invested Capital Growth	183.78%	99.91%	170.49%	104.69%	70.04%	59.91%	0.52%	-10.74%	-15.57%	-9.57%
Revenue Q/Q Growth	0.79%	19.42%	-23.27%	33.99%	-3.41%	21.32%	-22.97%	3.92%	10.47%	11.60%
EBITDA Q/Q Growth	312.22%	134.99%	-340.01%	39.66%	26.56%	211.27%	-284.54%	17.13%	105.66%	1,042.12%
EBIT Q/Q Growth	179.91%	137.70%	-583.22%	29.71%	29.44%	158.67%	-424.10%	14.56%	86.34%	400.43%
NOPAT Q/Q Growth	291.65%	-93.65%	-11,314.47%	24.95%	29.66%	95.95%	-4,027.33%	20.56%	-326.56%	110.96%
Net Income Q/Q Growth	331.62%	128.66%	-283.08%	35.54%	-47.13%	185.24%	-212.10%	-69.14%	109.02%	924.65%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	20.51%	182.53%	-53.85%	-199.72%	-48.74%	324.39%	-58.40%	56.79%	113.10%	-84.90%
Free Cash Flow Firm Q/Q Growth	-23.44%	14.17%	-109.38%	17.19%	19.13%	14.04%	83.39%	192.00%	-174.94%	371.97%
Invested Capital Q/Q Growth	22.46%	8.68%	49.14%	3.12%	1.72%	2.21%	-6.25%	-8.42%	-3.78%	9.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.36%	60.77%	56.72%	56.67%	56.62%	56.75%	51.30%	54.56%	56.32%	58.55%
EBITDA Margin	4.17%	8.20%	-25.64%	-11.55%	-8.78%	8.05%	-19.29%	-15.38%	0.79%	8.07%
Operating Margin	3.36%	0.17%	-32.79%	-18.37%	-13.38%	-0.23%	-23.93%	-18.29%	-8.25%	5.20%
EBIT Margin	2.26%	4.50%	-28.34%	-14.87%	-10.86%	5.25%	-22.09%	-18.17%	-2.25%	6.05%
Profit (Net Income) Margin	4.02%	7.69%	-18.35%	-8.83%	-13.45%	9.45%	-13.75%	-22.38%	1.83%	16.78%
Tax Burden Percent	87.89%	90.37%	75.30%	66.54%	154.27%	133.86%	68.60%	145.20%	599.36%	93.41%
Interest Burden Percent	202.19%	189.15%	86.01%	89.28%	80.30%	134.43%	90.74%	84.86%	-13.57%	296.95%
Effective Tax Rate	12.11%	9.63%	0.00%	0.00%	0.00%	-33.86%	0.00%	0.00%	-499.36%	6.59%
Return on Invested Capital (ROIC)	7.59%	0.42%	-45.79%	-24.20%	-16.93%	-0.57%	-27.60%	-21.34%	-84.60%	7.84%
ROIC Less NNEP Spread (ROIC-NNEP)	7.47%	-0.61%	-46.31%	-24.82%	-16.31%	-2.44%	-28.07%	-19.79%	-93.94%	5.30%
Return on Net Nonoperating Assets (RNNOA)	-6.55%	0.52%	37.03%	19.27%	12.34%	1.81%	19.69%	14.02%	66.36%	-3.64%
Return on Equity (ROE)	1.04%	0.94%	-8.76%	-4.93%	-4.59%	1.24%	-7.91%	-7.32%	-18.25%	4.20%
Cash Return on Invested Capital (CROIC)	0.00%	-72.45%	-101.80%	-83.61%	-70.97%	-64.50%	-15.69%	-3.89%	2.80%	-1.52%
Operating Return on Assets (OROA)	0.62%	1.50%	-9.31%	-5.13%	-3.90%	2.00%	-8.73%	-7.12%	-0.89%	2.44%
Return on Assets (ROA)	1.10%	2.57%	-6.03%	-3.05%	-4.84%	3.60%	-5.43%	-8.77%	0.73%	6.77%
Return on Common Equity (ROCE)	1.04%	0.94%	-8.76%	-4.93%	-4.59%	1.24%	-7.91%	-7.32%	-18.25%	4.20%
Return on Equity Simple (ROE_SIMPLE)	-0.58%	0.00%	-0.51%	-1.38%	-3.35%	0.00%	-2.93%	-4.51%	-2.64%	0.00%
Net Operating Profit after Tax (NOPAT)	1.20	0.08	-8.51	-6.39	-4.49	-0.18	-7.51	-5.97	-25	2.79
NOPAT Margin	2.95%	0.16%	-22.95%	-12.86%	-9.36%	-0.31%	-16.75%	-12.80%	-49.44%	4.85%
Net Nonoperating Expense Percent (NNEP)	0.12%	1.03%	0.51%	0.62%	-0.62%	1.87%	0.47%	-1.55%	9.33%	2.54%
Return On Investment Capital (ROIC_SIMPLE)	-	0.02%	-	-	-	-0.05%	-	-	-	0.70%
Cost of Revenue to Revenue	33.64%	39.23%	43.28%	43.33%	43.38%	43.25%	48.70%	45.44%	43.68%	41.45%
SG&A Expenses to Revenue	19.87%	21.75%	32.57%	21.71%	21.56%	18.47%	25.43%	25.09%	21.25%	15.78%
R&D to Revenue	21.37%	20.17%	26.89%	24.42%	23.27%	18.67%	21.84%	21.45%	19.19%	16.92%
Operating Expenses to Revenue	63.00%	60.60%	89.52%	75.04%	70.00%	56.98%	75.23%	72.86%	64.57%	53.35%
Earnings before Interest and Taxes (EBIT)	0.92	2.18	-11	-7.39	-5.21	3.06	-9.91	-8.47	-1.16	3.48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.69	3.96	-9.51	-5.74	-4.21	4.69	-8.65	-7.17	0.41	4.64
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.76	3.24	2.94	2.73	1.81	3.15	2.24	1.88	1.89	2.11
Price to Tangible Book Value (P/TBV)	4.93	3.35	3.28	3.04	2.01	3.49	2.48	2.08	2.09	2.33
Price to Revenue (P/Rev)	15.21	8.39	7.49	6.60	4.11	6.40	4.37	3.70	3.62	4.17
Price to Earnings (P/E)	0.00	534.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	21.87	12.67	7.76	6.86	3.64	7.47	4.97	4.07	4.19	4.74
Enterprise Value to Revenue (EV/Rev)	12.59	6.30	5.68	4.90	2.54	5.04	3.03	2.30	2.24	2.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	215.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	236.84	184.33	95.20	29.50	13.70	21.99
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	136.73	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	-0.85	-0.80	-0.78	-0.76	-0.74	-0.70	-0.71	-0.71	-0.69
Leverage Ratio	1.16	1.18	1.22	1.22	1.22	1.24	1.25	1.24	1.26	1.26
Compound Leverage Factor	2.35	2.24	1.05	1.09	0.98	1.67	1.13	1.05	-0.17	3.74
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	15.54	10.01	8.42	7.95	5.41	8.46	6.35	5.69	5.21	5.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.70	9.26	7.53	7.93	7.20	6.97	6.99	7.33	6.21	5.86
Quick Ratio	9.19	7.95	6.05	6.50	5.85	5.66	5.77	6.14	5.26	5.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-47	-41	-85	-70	-57	-49	-8.14	7.49	-5.61	15
Operating Cash Flow to CapEx	-676.04%	94.84%	443.79%	-242.76%	-318.72%	617.66%	697.88%	589.17%	1,335.45%	284.07%
Free Cash Flow to Firm to Interest Expense	-72.98	-59.18	-126.49	-172.36	-95.82	-124.38	-18.46	55.90	-47.17	0.00
Operating Cash Flow to Interest Expense	-11.56	9.01	4.25	-6.97	-7.12	24.14	8.97	46.30	111.10	0.00
Operating Cash Flow Less CapEx to Interest Expense	-13.27	-0.49	3.29	-9.84	-9.36	20.23	7.69	38.44	102.78	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.27	0.33	0.33	0.35	0.36	0.38	0.40	0.39	0.40	0.40
Accounts Receivable Turnover	3.77	4.17	4.52	4.06	3.85	3.68	4.30	4.19	3.72	3.44
Inventory Turnover	1.49	1.57	1.20	1.26	1.33	1.53	1.44	1.54	1.60	1.71
Fixed Asset Turnover	20.32	16.80	15.06	15.32	14.50	12.03	11.88	11.73	11.20	11.02
Accounts Payable Turnover	11.93	16.09	11.42	14.27	14.95	21.33	19.85	28.39	17.96	20.87
Days Sales Outstanding (DSO)	96.75	87.47	80.78	89.83	94.72	99.08	84.90	87.01	97.99	106.08
Days Inventory Outstanding (DIO)	245.80	232.46	305.42	288.94	274.21	238.05	253.67	237.36	228.71	214.00
Days Payable Outstanding (DPO)	30.59	22.69	31.97	25.57	24.42	17.11	18.39	12.86	20.32	17.49
Cash Conversion Cycle (CCC)	311.96	297.25	354.24	353.20	344.51	320.02	320.18	311.52	306.38	302.60
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	75	81	122	125	128	130	122	112	108	118
Invested Capital Turnover	2.57	2.68	1.99	1.88	1.81	1.82	1.65	1.67	1.71	1.62
Increase / (Decrease) in Invested Capital	49	41	77	64	53	49	0.63	-13	-20	-12
Enterprise Value (EV)	1,640	1,033	943	860	465	973	607	455	451	558
Market Capitalization	1,982	1,377	1,245	1,159	753	1,236	878	733	729	836
Book Value per Share	$3.09	$3.16	$3.13	$3.13	$3.05	$2.90	$3.00	$2.96	$2.93	$3.07
Tangible Book Value per Share	$2.99	$3.05	$2.80	$2.81	$2.75	$2.61	$2.71	$2.68	$2.65	$2.79
Total Capital	417	426	423	424	416	393	393	389	385	396
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-342	-344	-302	-299	-288	-263	-270	-277	-278	-278
Capital Expenditures (CapEx)	1.11	6.53	0.64	1.17	1.33	1.54	0.57	1.05	0.99	0.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)	61	61	67	72	76	73	63	54	50	51
Debt-free Net Working Capital (DFNWC)	402	405	369	371	364	336	333	332	327	329
Net Working Capital (NWC)	402	405	369	371	364	336	333	332	327	329
Net Nonoperating Expense (NNE)	-0.43	-3.64	-1.71	-2.00	1.96	-5.69	-1.34	4.47	-26	-6.85
Net Nonoperating Obligations (NNO)	-342	-344	-302	-299	-288	-263	-270	-277	-278	-278
Total Depreciation and Amortization (D&A)	0.77	1.79	1.00	1.65	1.00	1.63	1.26	1.30	1.56	1.16
Debt-free, Cash-free Net Working Capital to Revenue	46.69%	37.15%	40.46%	41.23%	41.29%	37.87%	31.20%	27.55%	24.64%	25.39%
Debt-free Net Working Capital to Revenue	308.75%	246.88%	222.27%	211.41%	198.57%	173.99%	165.89%	167.77%	162.71%	164.02%
Net Working Capital to Revenue	308.75%	246.88%	222.27%	211.41%	198.57%	173.99%	165.89%	167.77%	162.71%	164.02%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	134.71M	134.51M	135.49M	135.92M	136.17M	135.28M	130.92M	131.44M	131.00M	130.61M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	138.71M	138.56M	135.49M	135.92M	136.17M	135.28M	130.92M	131.44M	132.79M	130.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	134.85M	135.43M	135.67M	136.36M	135.55M	130.82M	131.27M	131.51M	128.81M	128.10M
Normalized Net Operating Profit after Tax (NOPAT)	1.20	0.08	-8.51	-6.39	-4.49	-0.10	-7.51	-5.97	-2.97	2.79
Normalized NOPAT Margin	2.95%	0.16%	-22.95%	-12.86%	-9.36%	-0.16%	-16.75%	-12.80%	-5.77%	4.85%
Pre Tax Income Margin	4.57%	8.51%	-24.37%	-13.27%	-8.72%	7.06%	-20.05%	-15.42%	0.30%	17.96%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.41	3.17	-15.62	-18.06	-8.76	7.76	-22.47	-63.19	-9.72	0.00
NOPAT to Interest Expense	1.84	0.11	-12.65	-15.62	-7.55	-0.46	-17.04	-44.54	-213.96	0.00
EBIT Less CapEx to Interest Expense	-0.30	-6.34	-16.57	-20.93	-11.00	3.85	-23.76	-71.05	-18.04	0.00
NOPAT Less CapEx to Interest Expense	0.13	-9.39	-13.61	-18.49	-9.79	-4.37	-18.32	-52.40	-222.28	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-363.44%	0.00%	-261.11%	-485.89%	-358.99%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, four-year view of Cytek Biosciences (CTKB) using the quarterly income statements, cash flow statements, and balance sheets provided. All figures are in USD.

Q4 2024 Net income attributable to common shareholders rose to $9.64M on $57.48M revenue, marking a profitable quarter after several weaker periods.
Q4 2024 gross margin was robust, with Total Gross Profit of $33.65M on $57.48M revenue (roughly 58.5–59%), indicating solid profitability at the gross level.
Revenue trended up through 2024: Q1 2024 revenue of $44.86M, rising to Q4 2024 at $57.48M, a clear sequential growth pattern.
Cash from continuing operating activities remained positive across 2024, with approximately $3.96M in Q1, $6.20M in Q2, $13.22M in Q3, and $2.00M in Q4, signaling ongoing cash generation from core operations.
In Q4 2024, Cytek realized a $45.0M inflow from the sale/maturity of investments, providing a notable cash inflow within investing activities.
The balance sheet shows a strong equity base around $385–389M, with liabilities around $93–106M, suggesting a well-capitalized company with a sizable equity cushion.
Weighted-average shares outstanding in 2024 varied modestly across quarters (e.g., Q4 2024: 128.10M basic/diluted; Q3: 132.79M; Q2: 131.44M; Q1: 135.28M), indicating some fluctuation in potential diluted EPS but no dramatic dilution signals.
Investing activities show ongoing positioning in investments, with both substantial purchases and some disposals across quarters (e.g., large purchases of investments in multiple quarters and notable sales in others), resulting in net investing cash outflows that are common for a growth-focused biotech platform.
Current liabilities hovered in the mid-to-high $50Ms to low $60Ms in 2024, reflecting ongoing day-to-day liquidity needs but not signaling immediate distress given the strong equity base.
Q2 2024 and Q1 2024 included meaningful net losses on a net income to common basis (Q2 2024: -$10.43M; Q1 2024: -$6.17M), illustrating profitability volatility within the year.
Cash burn from investing activities remained substantial in 2024 (e.g., Q4 2024 net cash from continuing investing activities was deeply negative despite the $45M investment sale), contributing to a sizable overall cash outflow in the quarter.
Net change in cash was negative in the Q3 and especially Q4 2024 quarters (-$15.62M and -$63.56M, respectively), indicating meaningful cash outflows despite positive operating cash flow in parts of the year.
Total liabilities rose across the period (e.g., Q3 2024 Total Current Liabilities around $62.8M and Total Liabilities around $105.8M), suggesting increasing liabilities that investors should monitor relative to growing assets and equity.

05/21/26 02:46 PM ETAI Generated. May Contain Errors.

Cytek Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cytek Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Cytek Biosciences' net income appears to be on an upward trend, with a most recent value of -$6.02 million in 2024, falling from $2.48 million in 2022. The previous period was -$12.15 million in 2023. See Cytek Biosciences' forecast for analyst expectations on what's next for the company.

Cytek Biosciences' total operating income in 2024 was -$20.52 million, based on the following breakdown:

Total Gross Profit: $111.11 million
Total Operating Expenses: $131.63 million

Over the last 2 years, Cytek Biosciences' total revenue changed from $164.04 million in 2022 to $200.45 million in 2024, a change of 22.2%.

Cytek Biosciences' total liabilities were at $103.76 million at the end of 2024, a 2.3% increase from 2023, and a 10.5% increase since 2022.

In the past 2 years, Cytek Biosciences' cash and equivalents has ranged from $98.72 million in 2024 to $296.60 million in 2022, and is currently $98.72 million as of their latest financial filing in 2024.

Over the last 2 years, Cytek Biosciences' book value per share changed from 3.16 in 2022 to 3.07 in 2024, a change of -2.6%.

Related Companies

Financial statements for NASDAQ:CTKB last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Financials

Financials Breakdown Chart

Key Financial Trends

Cytek Biosciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Financials

Annual Income Statements for Cytek Biosciences

Quarterly Income Statements for Cytek Biosciences

Annual Cash Flow Statements for Cytek Biosciences

Quarterly Cash Flow Statements for Cytek Biosciences

Annual Balance Sheets for Cytek Biosciences

Quarterly Balance Sheets for Cytek Biosciences

Annual Metrics And Ratios for Cytek Biosciences

Quarterly Metrics And Ratios for Cytek Biosciences

Financials Breakdown Chart

Key Financial Trends

Cytek Biosciences Financials - Frequently Asked Questions

When does Cytek Biosciences' fiscal year end?

How has Cytek Biosciences' net income changed over the last 2 years?

What is Cytek Biosciences' operating income?

How has Cytek Biosciences' revenue changed over the last 2 years?

How much debt does Cytek Biosciences have?

How much cash does Cytek Biosciences have?

How has Cytek Biosciences' book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools